Introduction (Helen Tayton-Martin) 1. MAY 7, 2026 Business update Q1 2026 Helen Tayton-Martin, CEO Birgitte Rønø, CSO & COO Thomas Schmidt, CFO Mads Kronborg, VP Investor Relations and Communication Agenda R&D and AI-Immunology™ update (Birgitte Rønø) 2. Q1 2026 financial results (Thomas Schmidt) 3. Conclusive remarks (Helen Tayton-Martin) 4. 5. Q&A © Evaxion A/S. All rights reserved. 2 Forward-looking statement This presentation contains forward-looking statements within the meaning of Section 27A of the S ...